BridgeMD
New treatment option for Patient With Radiotherapy (Linac MRI)
Official title Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile Lesions
ClinicalTrials.gov ID: NCT05783908
What this study is testing
What is With non-magnetic screen?
With non-magnetic screen is an investigational medicine, being studied as a potential treatment for patient with radiotherapy (linac mri).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The patients eligible for the study are those treated by radiotherapy on Linac MRI for a mobile cancerous lesion (pancreas, liver, kidneys, adrenals, lung, adenopathy above or below the diaphragm ...). After signing the consent form, each patient will be randomized to one of two treatment arms: Standard arm : Radiotherapy treatment with Linac MRI without non-magnetic shielding Experimental arm : radiotherapy treatment with Linac MRI with non-magnetic screen The aim is to evaluate the effect of using a non-magnetic screen visible to the patient in the bunker during radiotherapy sessions delivered by Linac MRI on decreasing the ratio between the actual treatment time and the treatment time predicted by the machine.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Patient is at least 18 years old
- Patient starting radiotherapy on Linac MRI for a mobile cancerous lesion most often in the pancreas, liver, kidneys, adrenals, lung, supra or...
- Patient affiliated to the social security system
You likely can't join if
- Patient with lesions not detected by the device's tracking system
- Patient with visual disturbances
- Contraindications to treatment with Linac MRI (epileptic patients, pregnant or breastfeeding women, metallic prosthesis or pacemaker not compatible...
- Patients with cognitive disorders
- Persons deprived of liberty or under guardianship (including curatorship)
- Pregnant or nursing woman
See the full eligibility criteria
- Patient is at least 18 years old
- Patient starting radiotherapy on Linac MRI for a mobile cancerous lesion most often in the pancreas, liver, kidneys, adrenals, lung, supra or subdiaphragmatic adenopathy
- Patient affiliated to the social security system
- Patient with lesions not detected by the device's tracking system
- Patient with visual disturbances
- Contraindications to treatment with Linac MRI (epileptic patients, pregnant or breastfeeding women, metallic prosthesis or pacemaker not compatible with MRI)
- Patients with cognitive disorders
- Persons deprived of liberty or under guardianship (including curatorship)
- Pregnant or nursing woman
- Refusal to participate in the study
The study team makes the final eligibility decision.
Where it's taking place
- Dijon, Côte d'Or, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 months and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Dijon, Côte d'Or, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.